PD1 and PDL1 inhibitors (in short, PDx) have revolutionized cancer care since the approval of pembrolizumab for melanoma in 2014. Since then, the field has expanded both in terms of the number of approved PDx and the range of indications. However, despite this dramatic progress, a portion of patients across malignancies do not respond or develop resistance to treatment. Over the past few years, the field has faced the challenge of finding novel therapy combinations that can increase the efficacy of PDx in these patients.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The authors declare no competing interests.